Press Releases

HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will

Data show TTP399 improves glycemic control and insulin resistance without hypoglycemia NEW ORLEANS --(BUSINESS WIRE)--Jun. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for

HIGH POINT, N.C. --(BUSINESS WIRE)--May 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and reported

Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 20, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and

HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected

HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President

HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 4, 2016-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President

- Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer’s disease - Completed enrollment of AGATA Phase 2b study with liver-selective Glucokinase Activator in Type 2 diabetes, with expected data readout in mid-2016 - Initiated LOGRA Phase 2b study with oral GLP-1R agonist in Type 2

Data presented at Keystone Symposia on Molecular and Cellular Biology KEYSTONE, Colo. --(BUSINESS WIRE)--Feb. 22, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s

Oral Glucokinase Activator has potential to address an underlying cause of Type 2 diabetes Company expects to report topline results in mid-2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 9, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the

HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 28, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President

TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Topline results are expected at the end of 2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 21, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development

Brings Decades of Pharmaceutical Research and Management Experience, Including Serving in Senior Roles at Pfizer and Eli Lilly Company HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 2, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that Larry Altstiel has joined the company as Chief Medical

HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 24, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, announced that Stephen Holcombe , President

HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 13, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that Stephen Holcombe ,

HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 12, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today reported financial results for the

HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 22, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Dr.

HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 28, 2015-- First paragraph, second sentence of release dated September 23, 2015 , should read: The presentation will take place at 2:00 pm EDT on Tuesday, September 29 at the Sofitel Hotel in New York City (instead of: The presentation will take place at

HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 23, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President

HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 29, 2015-- vTv Therapeutics Inc. (the “Company”) (Nasdaq:VTVT) announced today the pricing of its initial public offering of 7,812,500 shares of its Class A common stock at a price to the public of $15.00 per share.

vTv Therapeutics Inc. (the “Company”) today announced the launch of its initial public offering in the United States of 7,812,500 shares of its Class A common stock. The initial public offering price is currently expected to be between $15.00 and $17.00 per share of Class A common stock.  The

High Point, North Carolina (June 29, 2015) vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the appointment of Rudy C.

High Point, North Carolina (June 15, 2015)   vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates, today announced it has filed a registration statement on Form S-1 with the U.S.

In a 6 Week Phase 2a Study, Treatment Showed Statistically Significant and Clinically Meaningful Reduction in A1c Levels High Point, North Carolina (June 4, 2015) vTv Therapeutics LLC announced today that it has initiated dosing of the AGATA study, a phase 2b clinical trial assessing the efficacy

Completed Phase 2 Trial Showed Positive Results Combating Alzheimer’s Disease High Point, North Carolina (May 19, 2015) vTv Therapeutics LLC (vTv) today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy),